Literature DB >> 1453319

The identification and tracking of Candida albicans isolates from oral lesions in HIV-seropositive individuals.

S H Miyasaki1, J B Hicks, D Greenspan, I Polacheck, L A MacPhail, T C White, N Agabian, J S Greenspan.   

Abstract

Restriction fragment polymorphism analysis was used to investigate the identity and genotypic relatedness of Candida albicans strains isolated from human immunodeficiency virus (HIV)-infected patients with or without oral candidiasis and from some of their sexual partners. Use of the species-specific DNA probe Ca3 revealed that most subjects carried a single distinct C. albicans strain throughout the course of the study, during both symptomatic and asymptomatic periods. Sexual partners were more likely to carry the same or similar C. albicans isolates than unrelated subjects, raising the possibility of transmission via intimate contact. One patient appeared to acquire his partner's isolate, which then became predominant in both partners in subsequent isolations. These findings indicate that recurrent oral candidiasis is usually caused by a single persistent strain unique to each patient, but that in some cases transmission via intimate contact may occur between sexual partners.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453319

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  14 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting.

Authors:  P Boerlin; F Boerlin-Petzold; J Goudet; C Durussel; J L Pagani; J P Chave; J Bille
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 3.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

4.  Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals.

Authors:  Kaaren G Vargas; Sophie Joly
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

5.  Characterization and partial nucleotide sequence of the DNA fingerprinting probe Ca3 of Candida albicans.

Authors:  J Anderson; T Srikantha; B Morrow; S H Miyasaki; T C White; N Agabian; J Schmid; D R Soll
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

6.  Molecular probe for typing strains of Candida albicans.

Authors:  P Postlethwait; B Bell; W T Oberle; P Sundstrom
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

7.  Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients.

Authors:  N Troillet; C Durussel; J Bille; M P Glauser; J P Chave
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

8.  Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients.

Authors:  F Dronda; M Alonso-Sanz; F Laguna; F Chaves; J V Martínez-Suárez; J L Rodríguez-Tudela; A González-López; E Valencia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

9.  Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients.

Authors:  M W Ollert; C Wende; M Görlich; C G McMullan-Vogel; M Borg-von Zepelin; C W Vogel; H C Korting
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

Review 10.  Candida albicans secreted aspartyl proteinases in virulence and pathogenesis.

Authors:  Julian R Naglik; Stephen J Challacombe; Bernhard Hube
Journal:  Microbiol Mol Biol Rev       Date:  2003-09       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.